{
    "clinical_study": {
        "@rank": "58838", 
        "arm_group": {
            "arm_group_label": "mRCC patients assessed with Perfusion CT", 
            "description": "Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent\u00ae), Pazopanib (Votrient \u00ae), Sorafenib (Nexavar\u00ae) evaluated with Perfusion-CT"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT)\n      for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC)\n      undergoing antiangiogenetic therapy (AAT) with multikinase inhibitors.\n\n      In this study patients with mRCC under AAT will be examined with 3 serial Perfusion - CT\n      scans - partially intergrated in their regular staging CT scheme - at baseline (before AAT\n      start),  1 week after AAT as well as 8 weeks after AAT initialization. Thereby selected\n      intrabdomial or intrathoracic metastases will be monitored longitudinally with perfusion CT.\n      Pretreament and post-treament perfusion characteristics of the assessed metastatic lesions\n      will be quantified and correlated with patient outcome."
        }, 
        "brief_title": "Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Renal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with metastasized renal cell carcinoma treated at the Department of Urology\n        (University of Munich - Grosshadern Campus)\n\n        1)  with either - Sunitinib (Sutent\u00ae),   Pazopanib (Votrient \u00ae) bzw. Sorafenib (Nexavar\u00ae)\n        as first-line therapy\n\n        2.)  with Sunitinib (Sutent\u00ae),   Pazopanib (Votrient \u00ae) bzw. Sorafenib (Nexavar\u00ae) as\n        second-line therapy after failed first-line therapy, who are off therapy for at least 2\n        weeks\n\n        and who have given informed consent to participate in the study\n\n        Exclusion Criteria:\n\n        Patients who have:\n\n          -  not given informed consent\n\n          -  known iodine allergy\n\n          -  high grade renal insuffiency (eGFR < 30ml/min) not on dialysis\n\n          -  overt hyperthyreoidism\n\n          -  singular metastases <1cm in diameter\n\n          -  an increase of their baseline creatine levels of >20% between CT examinations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic renal cell cancer eligible for AAT (antiangiogenic therapy) with\n        either Sunitinib (Sutent\u00ae), Pazopanib (Votrient \u00ae), Sorafenib (Nexavar\u00ae)   presenting at\n        the Departement of Urology. LMU, meeting the inclusion/exclusion criteria"
            }
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086734", 
            "org_study_id": "CTP NK 2012"
        }, 
        "intervention": {
            "arm_group_label": "mRCC patients assessed with Perfusion CT", 
            "description": "Baseline Perfusion CT-Scan (before AAT)\nFollow-Up I Perfusion-CT Scan 7 days after start with AAT\nFollow-Up II Perfusion-CT Scan 8 weeks after start with AAT", 
            "intervention_name": "Perfusion-CT", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Angiogenesis Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Perfusion-CT", 
            "mRCC", 
            "antiangiogenic therapy", 
            "response assessment"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "contact": {
                "email": "jozefina.casuscelli@med.uni-muenchen.de", 
                "last_name": "Jozefina Casuscelli, Dr. med.", 
                "phone": "+4989/7095-0"
            }, 
            "contact_backup": {
                "email": "alexander.sterzik@med.uni-muenchen.de", 
                "last_name": "Alexander Sterzik, Dr. med.", 
                "phone": "+4989/7095-0"
            }, 
            "facility": {
                "address": {
                    "city": "M\u00fcnchen", 
                    "country": "Germany", 
                    "state": "Bavaria", 
                    "zip": "81377"
                }, 
                "name": "Urologische Klinik und Poliklinik der Universit\u00e4t M\u00fcnchen"
            }, 
            "investigator": [
                {
                    "last_name": "Jozefina Casuscelli, Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Alexander Sterzik, Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Katharina Hellbach, Dr. med.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Martina Karpitschka, Dr. med.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Ingrisch, Dr. med.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma", 
        "overall_contact": {
            "last_name": "Alexander Sterzik, Dr. med.", 
            "phone": "+4989/7095-0"
        }, 
        "overall_official": [
            {
                "affiliation": "Urologische Klinik und Poliklinik der Universit\u00e4t M\u00fcnchen", 
                "last_name": "Michael Staehler, PD Dr. med.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Institut f\u00fcr Klinische Radiologie des Klinikums der Universit\u00e4t M\u00fcnchen", 
                "last_name": "Anno Graser, PD Dr. med.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Institut f\u00fcr Klinische Radiologie des Klinikums der Universit\u00e4t M\u00fcnchen", 
                "last_name": "Alexander Sterzik, Dr. med.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Urologische Klinik und Poliklinik der Universit\u00e4t M\u00fcnchen", 
                "last_name": "Jozefina Casuscelli, Dr. med.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prediction of progression-free interval and overall survival after initialization of antiangiogenic therapy based on baseline values and relative changes of CT perfusion parameters", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086734"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ludwig-Maximilians - University of Munich", 
            "investigator_full_name": "Dr. Jozefina Casuscelli", 
            "investigator_title": "Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Correlation of CT perfusion parameters at baseline as well as their relative changes after start of antiangiogenic therapy with response status according to RECIST 1.1", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "source": "Ludwig-Maximilians - University of Munich", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Siemens Healthcare Diagnostics Inc", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Bayer", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ludwig-Maximilians - University of Munich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}